CytomX Therapeutics第四季度GAAP每股收益$0.23,超出$(0.20)预期,销售额$38.09M超出$19.42M预期

财报速递2025-03-07
CytomX Therapeutics (NASDAQ:CTMX) 报告季度每股收益$0.23,超过分析师共识预期的$(0.20),增长215%。 与去年同期的每股收益$0.01相比增加了2200%。 公司报告季度销售额为$38.09百万,超过分析师共识预期的$19.42百万,增长96.19%。 与去年同期的销售额$26.61百万相比增加了43.17%。

以上内容来自Benzinga Earnings专栏,原文如下:

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $(0.20) by 215 percent. This is a 2200 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $38.09 million which beat the analyst consensus estimate of $19.42 million by 96.19 percent. This is a 43.17 percent increase over sales of $26.61 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法